March 3, 2026Open Access

Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring SMARCA4 mutations

Key Points

Patients with SMARCA4 mutations showed poorer therapeutic responses to EGFR-TKIs compared to non-mutants.
Among these patients, males and smokers were the predominant demographics.
Chemotherapy combined with anti-angiogenesis was more effective for Stage IV SMARCA4-mutant lung adenocarcinoma.
The findings indicate a need for tailored treatment approaches for NSCLC patients with SMARCA4 mutations.

Abstract

SMARCA4 mutations were predominantly males and smokers in NSCLC. SMARCA4 mutations conferred a poorer response for EGFR-mutant LUAD subgroups who received EGFR-TKIs. Additionally, chemotherapy plus anti-angiogenesis as first-line therapy may be more effective for Stage IV-SMARCA4 mutant LUAD with EGFR wt.

Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring SMARCA4 mutations

Key Points

Abstract

Cite This Study